Short answer
CRISPR Therapeutics AG (CRSP) filed its Q3 2026 10-Q quarterly report on Nov 2, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $13M (up 1325.1% year over year) with net income of −$111M.
Q3 2026 key financials · XBRL
- Revenue
- $13M
- +1325.1% YoY · +24.4% QoQ
- Net income
- −$111M
- −4.7% YoY · −22.3% QoQ
- Operating margin
- -1026.5%
- EPS (diluted)
- −$1.16
- −1.8% YoY · −23.4% QoQ
Source: XBRL data from the CRISPR Therapeutics AG (CRSP) Q3 2026 10-Q on SEC EDGAR. USD.
CRISPR Therapeutics AG Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $12.7M vs $0.0M YoY, primarily $12.3M deferred Vertex collaboration revenue
- Net loss $111.4M vs $106.4M YoY, operating loss $130.0M vs $132.1M
- R&D expense $71.9M vs $58.9M, worst cost increase external R&D $25.1M vs $14.9M
- Cash, equivalents and securities $2,276.6M; operating cash used $282.1M for nine months
- $585.4M net convertible-note proceeds; cash runway at least 24 months, additional financing expected for long-term development
Risk Factors
- No material changes to previously disclosed risk factors in the December 31, 2025 Form 10-K
- Continued business, financial condition, and operating-results exposure from previously disclosed risks
- Prior-quarter risk disclosures remain applicable through the quarter ended March 31, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CRISPR Therapeutics AG quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.